Pharmaceutical intermediates

Imatinib Intermediates

3 pharmaceutical intermediates for Imatinib. Indication: Chronic Myeloid Leukemia (CML); Acute Lymphoblastic Leukemia (ALL); Hypereosinophilic Syndrome (HES); Myelodysplastic-Myeloproliferative Neoplasms; Chronic Eosinophilic Leukemia (CEL); Myelodysplastic Syndrome (MDS); Dermatofibrosarcoma Protuberans; Systemic Mastocytosis; Chronic Myelogenous Leukemia (CML); Gastrointestinal Stromal Tumor (GIST).

提交项目 All intermediates

About Imatinib

Originator: Novartis Pharmaceuticals Corp
Indication: Chronic Myeloid Leukemia (CML); Acute Lymphoblastic Leukemia (ALL); Hypereosinophilic Syndrome (HES); Myelodysplastic-Myeloproliferative Neoplasms; Chronic Eosinophilic Leukemia (CEL); Myelodysplastic Syndrome (MDS); Dermatofibrosarcoma Protuberans; Systemic Mastocytosis; Chronic Myelogenous Leukemia (CML); Gastrointestinal Stromal Tumor (GIST)
Approved Date: 05/10/2001

Available intermediates

3 intermediates currently listed for Imatinib. Request specifications, documentation or a quotation for any item below.

Imatinib intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine	152460-10-1	/	/
1-(3-Pyridyl)-3-(dimethylamino)-2-propen-1-one	55314-16-4	/	/
4-[(4-Methylpiperazin -1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3- ylpyrimidin-2-yl)amino]phenyl]benzamide	152459-95-5	/	/

Other programs under I

Ibrutinib/ Zanubrutinib Iguratimod Imeglimin hydrochloride Indacaterol Maleate Infigratinib Ipatacopan Hydrochloride Ipragliflozin Irinotecan

Building toward Imatinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →